| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Elderly, Children, Adult |
| State: | Powder |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product name | Baloxavir Marboxil |
| Cas number | 1985606-14-1 |
| Appearance | White powder |
| MF | C27H23F2N3O7S |
| MW | 571.6 |
Baloxavir marboxil is used to treat influenza A and influenza B infections. The drug was initially approved for marketing in Japan in February 2018, and was approved by the FDA on October 24, 2018 for the treatment of acute uncomplicated influenza patients 12 years of age and older who have symptoms for no more than 48 hours. Baloxavir marboxil is a cap endonuclease inhibitor, which has a unique mechanism of action compared with the class of neuraminidase inhibitor drugs currently used to treat influenza infections.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}